Capecitabine (Xeloda®): From the laboratory to the patient's home

Clinical Colorectal Cancer

Volumn 2, Issue 1, 2002, Pages 16-23

  Pentheroudakis, George ^a   Twelves, Chris ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Capecitabine; Chemotherapy; Colorectal cancer; Fluoropyrimidines

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER TISSUE; CENTRAL VENOUS CATHETERIZATION; CLINICAL LABORATORY; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HOME; HOSPITALIZATION; HUMAN; INTESTINE MUCOSA; LIVER TOXICITY; METASTASIS; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; REVIEW; STOMATITIS; COLORECTAL TUMOR; DRUG DESIGN; DRUG EFFECT; KIDNEY; LIVER; METABOLISM;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG DESIGN; HUMANS; KIDNEY; LIVER;

EID: 0036018886     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.007     Document Type: Review

References (48)

1. Fluorouracil: Biochemistry and pharmacology
2. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion
3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer
4. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
5. Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five standard chemotherapy regimens in three common tumors-Part one. Model projections for cost based on charges
6. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons
7. Patient preferences for oral versus intravenous palliative chemotherapy
8. Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration
9. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors
10. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
11. Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy-5-fluorocytidine
12. Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells
13. Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic human tissues
14. Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy-5-fluorocytidine
15. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
16. Capecitabine: Preclinical pharmacology studies
17. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
18. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
19. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
20. Thymidine phosphorylase is angiogenic and promotes tumor growth
21. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo
22. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
23. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
24. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
25. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
26. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
27. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
28. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
29. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
30. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
31. A phase III trial (S014796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
32. Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large phase III trials
33. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma
34. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
35. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
36. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
37. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
38. Safety profile and preliminary efficacy of capecitabine (Xeloda) in combination with oxaliplatin in patients with advanced or metastatic solid tumors: Results from a phase I study
39. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
40. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
41. Capecitabine in combination with oxaliplatin as first line therapy for patients with advanced or metastasis colorectal cancer: Preliminary results of an international multicenter phase II study
42. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer
43. Capecitabine named-patient program for patients with advanced breast cancer: The UK experience
44. Purification and properties of cytidine deaminase from normal and leukemic granulocytes
45. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
46. Effective dose-modification scheme for the management of toxicities with capecitabine therapy: Data from metastatic colorectal cancer phase III trials
47. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
48. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients